Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection
Kun Li, Zhuo Li, Christine Wohlford-Lenane, David K. Meyerholz, Rudragouda Channappanavar, Dong An, Stanley Perlman, Paul B. McCray, Biao He
Abstract
MERS-CoV causes lethal infection in humans, and there is no vaccine. Our work demonstrates that PIV5 is a promising vector for developing a MERS vaccine. Furthermore, success of PIV5-based MERS vaccine can be employed to develop a vaccine for emerging CoVs such as SARS-CoV-2, which causes COVID-19.
Topics & Concepts
VirologyMiddle East respiratory syndrome coronavirusImmunizationNasal administrationCoronavirusMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Recombinant DNABiologyImmunologyAntibodyInfectious disease (medical specialty)DiseaseBiochemistryPathologyGeneSARS-CoV-2 and COVID-19 ResearchRespiratory viral infections researchInfluenza Virus Research Studies